FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Abstract

Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).

Keywords

GemcitabineFOLFIRINOXMedicinePancreatic cancerOncologyAdjuvant therapyInternal medicineCancerIrinotecan

Affiliated Institutions

Related Publications

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Publication Info

Year: 2018
Type: article
Volume: 379
Issue: 25
Pages: 2395-2406
Citations: 2673
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2673

OpenAlex

Cite This

APA Style

                            
                                
                                    Thierry Conroy, 
                                
                                    Pascal Hammel, 
                                
                                    Mohamed Hebbar
                                
                                et al.
                            
                            (2018). 
                            FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. 
                            New England Journal of Medicine
                            , 379
                            (25)
                            , 2395-2406.
                            https://doi.org/10.1056/nejmoa1809775
                        

Identifiers

DOI: 10.1056/nejmoa1809775